Literature DB >> 32666213

Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems.

Shannon L Gutenkunst1, Janette L Vardy2,3,4, Haryana M Dhillon4,5, Melanie L Bell6.   

Abstract

OBJECTIVE: Cognitive impairment negatively affects some cancer survivors who have completed chemotherapy; however, factors underlying this cognitive impairment remain poorly understood. We aimed to investigate (1) the relative importance of demographics, medical, and psychological characteristics associated with cognitive impairment and (2) the specific variables associated with cognitive impairment in adult cancer survivors who completed adjuvant chemotherapy.
METHODS: We performed post hoc analyses of baseline data from early-stage cancer survivors with cognitive complaints who received adjuvant chemotherapy 0.5-5 years earlier and volunteered for a trial designed to improve cognition. The primary outcome of self-reported cognitive impairment was measured using a questionnaire; secondary outcome of objective cognitive impairment was measured using a computerized neuropsychological test battery. Hierarchical linear regression determined the relative importance of demographics, medical, and psychological characteristics in associations with both self-reported and objective cognitive impairment.
RESULTS: The sample was 95% female and 89% breast cancer patients. The final model accounted for 33% of variation in self-reported cognitive impairment (n = 212, demographics 5%, medical 3%, and psychological 25%), with fatigue and stress as significant individual correlates (p values ≤ 0.0001). For the secondary analysis, the final model accounted for 19% of variation in objective cognitive impairment (n = 206, demographics 10%, medical 5%, and psychological 4%), with age, smoking history, and number of chemotherapy cycles as significant individual correlates.
CONCLUSION: We found that psychological characteristics are more important than demographic and medical characteristics in self-reported cognitive impairment, whereas other characteristics are more important in objective cognitive impairment. This suggests clinicians should investigate possible psychological problems in cancer survivors who self-report cognitive impairment.

Entities:  

Keywords:  Adjuvant chemotherapy; Cancer survivors; Cognitive impairment; Quality of life

Mesh:

Year:  2020        PMID: 32666213     DOI: 10.1007/s00520-020-05616-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  38 in total

Review 1.  Cognitive function after chemotherapy in adults with solid tumours.

Authors:  Janette Vardy; Ian Tannock
Journal:  Crit Rev Oncol Hematol       Date:  2007-09       Impact factor: 6.312

2.  Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy.

Authors:  Barbara Collins; Joyce Mackenzie; Giorgio A Tasca; Carole Scherling; Andra Smith
Journal:  J Int Neuropsychol Soc       Date:  2013-11-15       Impact factor: 2.892

Review 3.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

4.  Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy.

Authors:  Haryana M Dhillon; Ian F Tannock; Gregory R Pond; Corrinne Renton; Sean B Rourke; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2017-10-27       Impact factor: 4.442

5.  No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy.

Authors:  Mimi Mehlsen; Anders Degn Pedersen; Anders Bonde Jensen; Robert Zachariae
Journal:  Psychooncology       Date:  2009-03       Impact factor: 3.894

6.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer.

Authors:  Jeffrey S Wefel; Janette Vardy; Tim Ahles; Sanne B Schagen
Journal:  Lancet Oncol       Date:  2011-02-25       Impact factor: 41.316

7.  Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.

Authors:  Jeanne Debess; Jens Østergaard Riis; Malene Cramer Engebjerg; Marianne Ewertz
Journal:  Breast Cancer Res Treat       Date:  2010-03-20       Impact factor: 4.872

Review 8.  Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review.

Authors:  Amanda D Hutchinson; Jessica R Hosking; Ganessan Kichenadasse; Julie K Mattiske; Carlene Wilson
Journal:  Cancer Treat Rev       Date:  2012-06-02       Impact factor: 12.111

9.  Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.

Authors:  Nelli Boykoff; Mona Moieni; Saskia Karen Subramanian
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

10.  A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

Authors:  V Jenkins; V Shilling; G Deutsch; D Bloomfield; R Morris; S Allan; H Bishop; N Hodson; S Mitra; G Sadler; E Shah; R Stein; S Whitehead; J Winstanley
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  5 in total

1.  Correlates of common concerns in older cancer survivors of leukemia and lymphoma: results from the WHI LILAC study.

Authors:  Kah Poh Loh; Eric M McLaughlin; Jessica L Krok-Schoen; Oreofe O Odejide; Areej El-Jawahri; Lihong Qi; Aladdin H Shadyab; Lisa G Johnson; Electra D Paskett
Journal:  J Cancer Surviv       Date:  2022-08-18       Impact factor: 4.062

Review 2.  Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?

Authors:  Sanne B Schagen; Andrey S Tsvetkov; Annette Compter; Jeffrey S Wefel
Journal:  Nat Rev Neurol       Date:  2022-02-09       Impact factor: 44.711

3.  Factors associated with cognitive impairment during the first year of treatment for nonmetastatic breast cancer.

Authors:  Nicole Rodriguez; Jonathan M Fawcett; Joshua A Rash; Renee Lester; Erin Powell; Connor D MacMillan; Sheila N Garland
Journal:  Cancer Med       Date:  2021-01-16       Impact factor: 4.452

4.  Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy.

Authors:  Pin Lv; Guolin Ma; Wenqian Chen; Renyuan Liu; Xiaoyan Xin; Jiaming Lu; Shu Su; Ming Li; ShangWen Yang; Yiming Ma; Ping Rong; Ningyu Dong; Qian Chen; Xin Zhang; Xiaowei Han; Bing Zhang
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

5.  A Telehealth-Based Cognitive-Adaptive Training (e-OTCAT) to Prevent Cancer and Chemotherapy-Related Cognitive Impairment in Women with Breast Cancer: Protocol for a Randomized Controlled Trial.

Authors:  Ángela González-Santos; Maria Lopez-Garzon; Carmen Sánchez-Salado; Paula Postigo-Martin; Mario Lozano-Lozano; Noelia Galiano-Castillo; Carolina Fernández-Lao; Eduardo Castro-Martín; Tania Gallart-Aragón; Marta Legerén-Álvarez; Rocío Gil-Gutiérrez; Lydia Martín-Martín
Journal:  Int J Environ Res Public Health       Date:  2022-06-10       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.